Amicus Therapeutics (NASDAQ:FOLD) Posts Earnings Results, Misses Estimates By $0.07 EPS

Amicus Therapeutics (NASDAQ:FOLD) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.07), Zacks reports. Amicus Therapeutics had a negative net margin of 21.21% and a negative return on equity of 15.97%. Amicus Therapeutics updated its FY 2025 guidance to EPS.

Amicus Therapeutics Price Performance

NASDAQ FOLD opened at $9.85 on Wednesday. The company’s 50 day simple moving average is $9.60 and its two-hundred day simple moving average is $10.43. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. Amicus Therapeutics has a 1 year low of $8.78 and a 1 year high of $14.02.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at $8,884,273.08. The trade was a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.20% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Monday, January 13th. JPMorgan Chase & Co. raised their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Guggenheim boosted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Morgan Stanley reiterated an “equal weight” rating and set a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.88.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.